Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report

31 Jan 2022

Abstract excerpt

Docetaxel therapy occasionally causes severe and life-threatening toxicities. Some docetaxel toxicities are related to exposure, and inter-individual variability in exposure has been described based on genetic variation and drug-drug interactions that impact docetaxel clearance. Cytochrome P450 3A4 (CYP3A4) and CYP3A5 metabolize docetaxel into inactive metabolites, and this is the primary mode of docetaxel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to Colorectal Cancer Treatments and Studies
Share to Pharmacogenetics and Drug Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35174070
DOI: 10.3389/fonc.2021.809527

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case ReportPMID 35174070Read ↗

Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.Semantic proximity Read ↗

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.Semantic proximity Read ↗

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.Semantic proximity Read ↗

Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphismsSemantic proximity Read ↗

Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.Semantic proximity Read ↗

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.Semantic proximity Read ↗

Genetic associations of docetaxel-based chemotherapy-induced myelosuppression in Chinese Han population.Semantic proximity Read ↗

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.Semantic proximity Read ↗

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.Semantic proximity Read ↗

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.Semantic proximity Read ↗

Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting NeuropathySemantic proximity Read ↗

Pharmacogenetic pathway analysis of docetaxel elimination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.